Trending Industry Today: WUXI BIO Leads Gains In Biotechnology Stocks

Moomoo NewsMar 13 23:30 ET

WUXI XDC has been honored with multiple accolades at the 2025 "Asia-Pacific Biomedical Excellence Awards."

Shanghai, March 13, 2025 /PR Newswire/ -- WUXI XDC (stock code: 2268.HK), a global leader focused on providing end-to-end CRDMO services for antibody-drug conjugates (ADC) and other bioconjugates, today announced that the company has won four awards at the Asia-Pacific Biopharma Excellence Awards 2025. The Asia-Pacific Biopharma Excellence Awards aim to recognize companies that excel in the Biomedical industry each year.

PR NewswireMar 13 01:59 ET

WuXi XDC Wins Multiple Awards at Asia-Pacific Biopharma Excellence Awards 2025

PR NewswireMar 13 01:54 ET

WuXi XDC Cayman Inc. (HKG:2268) Shares Could Be 33% Below Their Intrinsic Value Estimate

Simply Wall StMar 12 18:19 ET

WuXi XDC and AbTis Announce Strategic Partnership to Advance Next-Generation ADCs

PR NewswireMar 11 09:20 ET

WUXI XDC and AbTis announce a strategic partnership to jointly advance the development of the next generation of ADC drugs.

On March 11, 2025, in Shanghai, China and Seoul, South Korea / PR Newswire / -- WUXI XDC (stock code: 2268.HK), a global leader focused on providing end-to-end CRDMO services for antibody-drug conjugates (ADC) and other bioconjugates, announced today the signing of a strategic cooperation memorandum of understanding (MOU) with the South Korean biotechnology company AbTis. This collaboration will deeply integrate AbTis' proprietary site-specific conjugation technology platform AbClick with WUXI XDC's integrated R&D services and one-stop research and production platform, aiming to create advanced site-specific conjugation technology for clients.

PR NewswireMar 11 09:17 ET